Industry
103d agoHarbour BioMed Debuts AI-Designed Obesity Drug Candidate
LET003 is the first drug candidate developed using the Hu-mAtrIx AI platform. Preclinical data shows the antibody targets ACVR2A/2B receptors to treat obesity. Harbour BioMed aims for best-in-class therapy status with this molecule.
The Signal
This incremental win validates the company's internal AI pipeline for protein engineering and therapeutic discovery.